Linagliptin and Mesenchymal Stem Cells: A Pilot Study
| Status: | Recruiting |
|---|---|
| Conditions: | Schizophrenia |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 45 |
| Updated: | 5/21/2016 |
| Start Date: | April 2015 |
| End Date: | May 2017 |
| Contact: | Brian Kirkpatrick, MD |
| Email: | bkirkpatrick@medicine.nevada.edu |
| Phone: | 775-682-8449 |
The purpose of the present study is to gather pilot data on the effects of linagliptin on
the concentration of the long and short forms of SDF1-α (stromal cell-derived factor alpha)
in humans, and to demonstrate the feasibility of such a study in patients with psychosis in
our setting.
the concentration of the long and short forms of SDF1-α (stromal cell-derived factor alpha)
in humans, and to demonstrate the feasibility of such a study in patients with psychosis in
our setting.
This study is a 13-week, open-label study of 8 participants with schizophrenia and minimal
thought disorder; they will have 12 weeks of treatment and week for assessment. They will
receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic
treatment. The principal outcome measures will be the concentrations of the long and short
forms of SDF1-α (stromal cell-derived factor alpha) in blood.
thought disorder; they will have 12 weeks of treatment and week for assessment. They will
receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic
treatment. The principal outcome measures will be the concentrations of the long and short
forms of SDF1-α (stromal cell-derived factor alpha) in blood.
Inclusion Criteria:
- Meets DSM (Diagnostic and Statistical Manual) criteria for schizophrenia.
- Considered clinically stable, and on the same dose of antipsychotic for two weeks.
- A score no greater than 3 on the PANSS (Positive and Negative Syndrome Scale)
Conceptual Disorganization item.
- Not taking any medications for diabetes, or any anti-inflammatories other than
occasional aspirin or acetaminophen. Not taking Clozapine.
- Age 18-45 years.
- Can be available for regular morning appointments from 8:00 am to 10:00 am,
preferably on Tuesdays, Wednesdays and Thursdays.
Exclusion Criteria:
- Does not meet DSM criteria for substance abuse or dependence.
- No serious current general medical condition, such as cancer, history of stroke or
myocardial infarction, tuberculosis, HIV/AIDS, hemophilia, etc.
We found this trial at
1
site
Reno, Nevada 89503
Principal Investigator: Brian Kirkpatrick, MD
Phone: 775-682-8449
Click here to add this to my saved trials
